Furthermore, the bone‐metastasis in vivo assay showed that overexpression of LGALS3 in HCC cells or mice pretreated with CM from LGALS3‐transduced HCC cells significantly enhanced the bone metastatic capability of HCC cells, as indicated by earlier systemic BM, and also promoted HCC‐mediated osteolytic bone disease, as shown by systemic severe osteolytic bone lesions, reduced systemic BMD, and higher frequency of SREs (Figure 3B,C and Figure S3K,L, Supporting Information). Here, LGALS3 is linked to hepatocellular carcinoma.